Last reviewed · How we verify

Minocycline vs Lymecycline — Competitive Intelligence Brief

Minocycline vs Lymecycline (Minocycline vs Lymecycline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Dermatology / Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Dermatology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Minocycline vs Lymecycline (Minocycline vs Lymecycline) — Darier. Both minocycline and lymecycline are tetracycline antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Minocycline vs Lymecycline TARGET Minocycline vs Lymecycline Darier marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis Doxycycline post-exposure prophylaxis University of Washington marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
topical tetracycline topical tetracycline Johns Hopkins University marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Neomycin Oral Product Neomycin Oral Product South Australian Health and Medical Research Institute marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
Doxycycline pre-operatively Doxycycline pre-operatively University of Pittsburgh marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Doxycycline Tablets Doxycycline Tablets Yaounde Central Hospital marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Tigecycline antimicrobial-lock solution Tigecycline antimicrobial-lock solution Clinica Universidad de Navarra, Universidad de Navarra marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

  1. OraPharma · 2 drugs in this class
  2. Vyne Therapeutics Inc. · 2 drugs in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
  5. Darier · 1 drug in this class
  6. Edward Lain, MD · 1 drug in this class
  7. Generic (originally Pfizer) · 1 drug in this class
  8. Galderma R&D · 1 drug in this class
  9. Johns Hopkins University · 1 drug in this class
  10. Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Minocycline vs Lymecycline — Competitive Intelligence Brief. https://druglandscape.com/ci/minocycline-vs-lymecycline. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: